Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer

• Published in: Anti-cancer drugs Vol. 31; no. 7; p. 702
• Main Authors: Zhang, Na, Sun, Pan, Jin, Haizhen, Yang, Yuqin, Zhao, Qingya, Zhou, Lin, Guo, Lili, Yang, Xiaohua, Lu, Liming
• Format: Journal Article
• Language: English
• Published: England 01.08.2020
• Subjects: Aminopyridines - administration & dosage; Aminopyridines - pharmacology; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; Benzamides - administration & dosage; Benzamides - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - enzymology; Carcinoma, Non-Small-Cell Lung - pathology; Cell Cycle - drug effects; Histone Deacetylase 6 - biosynthesis; Histone Deacetylase 6 - metabolism; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylases - biosynthesis; Histone Deacetylases - metabolism; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - enzymology; Lung Neoplasms - pathology; Paclitaxel - administration & dosage; Paclitaxel - pharmacology; Proto-Oncogene Proteins c-myc - antagonists & inhibitors; Proto-Oncogene Proteins c-myc - biosynthesis; Tumor Cells, Cultured
• ISSN: 1473-5741
• DOI: 10.1097/CAD.0000000000000935

The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer.